i remember you posting a bull case for nexavar expanding into asia a long while back. they recently received approval in south korea but overall sales for nexavar haven't been overwhelming.
since your post carfilzomib has emerged as a potential winner.
i would love to hear your current opinion of the company.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.